

# Munich Cancer Registry



- ▶ Incidence and Mortality
- ▶ Selection Matrix
- ▶ Homepage
- ▶ *Deutsch*

## ICD-10 C51-C58: Fem. genitale cancer

### Survival


Year of diagnosis	1988-1997	1998-2014
Patients	5,367	20,904
Diseases	5,425	21,336
Cases evaluated	4,874	16,609
Creation date	04/11/2016	
Export date	12/23/2015	
Population (females)	2.36 m	



Munich Cancer Registry at Munich Cancer Center  
Marchioninstr. 15  
Munich, 81377  
Germany

<http://www.tumorregister-muenchen.de/en>

<http://www.tumorregister-muenchen.de/en/facts/surv/sC5158E-ICD-10-C51-C58-Fem.-genitale-cancer-survival.pdf>




**Figure 1a.** Relative survival of patients with fem. genitale cancer by period of diagnosis. Included in the evaluation are 21,282 cases diagnosed between 1988 and 2014.

The survival results of the SEER program (Surveillance, Epidemiology, and End Results) of the American National Cancer Institute (NCI) are summarized as the period of diagnosis from 1998 to 2011, and are represented by gray diamonds in order to facilitate comparisons between MCR and SEER.

The presented survival curves are derived from clinical records with valid follow-up informations, which means that death certificate cases (DCO) cases are omitted from the analysis. With this one restriction, the MCR has provided population-based statistics since 1998, collecting data on all cancer cases in the region of southern Bavaria. Historical data of previous time periods can be heavily selected, therefore, univariate survival comparisons of the presented time periods must be carefully considered. Nonetheless, all calculable survival curves are depicted to facilitate the comparison of long time follow-up analyses of relative survival between particular cancers.

Years	Period of diagnosis					
	1988-1997 n=4,871		1998-2006 n=7,621		2007+ n=8,790	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0
1	86.9	88.8	85.0	86.9	85.8	87.6
2	76.1	79.4	75.2	78.3	76.5	79.5
3	69.3	73.8	68.1	72.2	70.0	74.1
4	64.4	69.9	63.3	68.4	65.4	70.4
5	61.0	67.5	60.0	66.0	62.0	67.9
6	58.1	65.7	56.8	63.6	59.3	66.1
7	55.1	63.6	54.4	62.0	56.3	63.8
8	52.8	62.1	52.2	60.7		
9	50.4	60.5	50.4	59.7		
10	48.8	59.7	48.8	58.9		
11	46.7	58.4	47.2	58.0		
12	45.2	57.7	45.7	57.4		
13	43.6	56.8	43.9	56.3		
14	41.7	55.5	42.0	55.0		
15	39.9	54.3	40.6	54.2		
16	38.5	53.5	38.8	53.1		
17	36.6	52.0				
18	35.2	51.2				
19	33.4	49.7				
20	31.9	48.6				


**Table 1b.** Observed (obs.) and relative (rel.) survival of patients with fem. genitale cancer by period of diagnosis for period 1988-2014 (N=21,282).




**Figure 2a.** Observed, expected and relative survival of the total cohort with fem. genitale cancer. Included in the evaluation are 21,282 cases diagnosed between 1988 and 2014.

Years	Group	
	Total cohort n=21,282	
	obs. %	rel. %
0	100.0	100.0
1	85.7	87.6
2	75.9	79.0
3	69.1	73.3
4	64.3	69.5
5	60.9	67.0
6	57.9	64.9
7	55.2	63.0
8	53.0	61.7
9	50.9	60.5
10	49.3	59.7
11	47.5	58.6
12	46.0	57.9
13	44.3	56.9
14	42.3	55.6
15	40.6	54.5
16	39.1	53.7
17	37.3	52.3
18	35.9	51.5
19	34.0	49.9
20	32.4	48.8

**Table 2b.** Observed (obs.) and relative (rel.) survival of the total cohort with fem. genitale cancer for period 1988-2014 (N=21,282).




**Figure 3a.** Observed survival of patients with fem. genitale cancer by age category. Included in the evaluation are 21,282 cases diagnosed between 1988 and 2014.



**Figure 3b.** Relative survival of patients with fem. genitale cancer by age category. Included in the evaluation are 21,282 cases diagnosed between 1988 and 2014.

Years	Age category									
	0-49 yrs n=4,017		50-59 yrs n=3,957		60-69 yrs n=5,361		70-79 yrs n=5,014		80+ yrs n=2,933	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	95.0	95.1	92.1	92.4	89.8	90.6	82.5	84.6	62.8	69.1
2	89.5	89.7	83.1	83.8	80.4	81.8	71.1	74.9	48.0	58.3
3	84.4	84.6	78.1	79.1	73.4	75.6	63.1	68.5	38.9	52.4
4	81.6	82.0	73.7	75.0	68.8	71.6	57.5	64.5	32.2	48.6
5	79.4	79.9	71.2	72.8	65.2	68.7	53.6	62.5	27.1	46.2
6	77.5	78.1	68.4	70.4	62.5	66.7	49.6	60.4	23.4	45.2
7	76.5	77.3	66.3	68.6	60.0	65.0	45.6	58.1	19.2	43.3
8	75.7	76.6	64.9	67.6	58.0	63.9	41.9	56.4	16.1	42.0
9	74.9	76.0	63.2	66.4	56.3	63.0	38.6	55.3	13.0	40.4
10	74.4	75.7	62.1	65.6	54.7	62.6	35.7	54.3	10.9	40.4
11	74.1	75.5	61.1	65.2	53.3	62.3	31.3	51.7	8.9	40.4
12	73.5	75.2	60.2	64.7	51.8	62.1	28.7	51.5		
13	72.8	74.7	58.8	63.9	50.1	61.7	25.4	50.1		
14	71.8	73.8	57.3	62.9	47.9	60.9	22.4	48.6		
15	70.9	73.1	56.1	62.3	45.9	60.4	19.1	46.6		
16	70.3	72.7	55.3	62.2	43.8	60.2	16.4	45.2		
17	68.9	71.7	53.9	61.5	41.7	60.0	13.4	42.8		
18	68.3	71.2	52.9	61.2	39.2	58.7	11.6	42.4		
19	67.1	70.4	50.9	60.0	36.4	58.4	9.1	39.2		
20	65.6	69.0	50.2	60.0	33.8	58.0				

**Table 3c.** Observed (obs.) and relative (rel.) survival of patients with fem. genitale cancer by age category for period 1988-2014 (N=21,282).




**Figure 4a.** Relative survival of patients with fem. genitale cancer by ICD-10 classification. Included in the evaluation are 21,282 cases diagnosed between 1988 and 2014.

ICD-10 classification														
Years	C51 Vulva n=1,345		C52 Vagina n=287		C53 Cervix uteri n=4,337		C54 Corpus uteri n=8,938		C55 Uterus unspec. n=49		C56 Ovary n=5,919		C57 Female genitals unspec. n=387	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	82.7	86.1	75.7	78.3	87.6	88.7	91.5	93.6	62.4	64.5	77.2	78.8	83.1	85.1
2	70.9	76.6	61.1	65.1	78.2	79.9	85.1	89.1	60.2	63.9	62.5	64.8	73.2	76.6
3	64.8	72.3	53.7	58.5	72.7	74.8	80.2	85.9	55.5	60.4	52.0	54.8	63.8	68.1
4	60.1	69.1	48.8	54.6	69.4	72.0	76.1	83.3	50.7	56.3	45.3	48.4	58.0	63.2
5	56.4	66.8	43.1	49.8	66.1	69.2	73.3	82.1	48.2	53.8	41.1	44.5	54.2	60.6
6	53.9	65.7	40.3	47.9	63.9	67.4	70.2	80.5	45.2	52.1	37.6	41.3	50.9	58.0
7	50.7	63.6	36.8	44.5	62.4	66.3	67.2	78.9			34.7	38.7	46.0	53.8
8	45.8	59.2	35.7	44.3	61.1	65.5	64.8	78.0			32.8	37.2	40.9	49.1
9	42.7	56.9	30.7	39.5	59.9	64.8	62.2	76.9			31.1	35.8	37.4	46.2
10	40.2	54.8	28.0	36.8	58.9	64.2	60.2	76.3			29.9	34.9	35.7	44.9

ICD-10 classification cont'd C58 Placenta n=20		
Years	obs. %	rel. %
0	100.0	100.0

**Table 4b.** Observed (obs.) and relative (rel.) survival of patients with fem. genitale cancer by ICD-10 classification for period 1988-2014 (N=21,282).



**Figure 4c.** Relative survival of patients with fem. genitale cancer by ICD-10 classification. Included in the evaluation are 16,411 cases diagnosed between 1998 and 2014.


ICD-10 classification														
Years	C51 Vulva		C52 Vagina		C53 Cervix uteri		C54 Corpus uteri		C55 Uterus unspec.		C56 Ovary		C57 Female genitals unspec.	
	n=1,117		n=201		n=3,155		n=7,014		n=31		n=4,563		n=315	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	83.5	86.9	75.4	78.1	87.5	88.4	91.3	93.4	53.3	53.5	76.2	77.9	81.1	83.0
2	71.1	76.8	58.5	62.5	78.7	80.2	85.1	88.9			62.1	64.5	71.6	75.0
3	65.0	72.6	51.0	55.5	73.5	75.3	80.5	85.9			51.0	53.7	61.6	65.7
4	59.6	68.7	47.2	52.7	70.5	72.8	76.5	83.4			44.2	47.3	55.7	61.1
5	56.2	66.6	43.1	49.4	67.5	70.2	73.6	82.0			39.9	43.3	51.5	57.7
6	54.1	66.2	41.6	49.3	65.6	68.5	70.3	80.0			36.2	39.9	47.9	55.0
7	51.1	64.4	37.3	45.3	64.3	67.6	67.4	78.5			33.5	37.5	43.3	50.8
8	45.1	58.8	37.3	45.3	63.0	66.6	65.2	77.7			31.8	36.1	40.5	48.8
9	41.7	55.9	34.7	44.6	62.1	66.2	63.0	77.0			30.2	34.8	38.9	47.7
10	39.8	54.5	31.8	41.4	61.5	65.9	60.9	76.2			28.8	33.8	36.1	46.0

ICD-10 classification		
cont'd	C58 Placenta	
	n=15	
Years	obs. %	rel. %
0	100.0	100.0

**Table 4d.** Observed (obs.) and relative (rel.) survival of patients with fem. genitale cancer by ICD-10 classification for period 1998-2014 (N=16,411).






**Figure 4e.** Relative survival of patients with fem. genitale cancer by extent of disease. For 19,918 of 21,282 cases diagnosed between 1988 and 2014 valid data could be obtained for this item. For a total of 19,787 cases an evaluable classification was established. The grey line represents the subgroup of 1,495 patients with missing values regarding extent of disease (7.0% of 21,282 patients, the percent values of all other categories are related to n=19,787).

Years	Extent of disease							
	Local n=15,018		Regional n=2,652		Distant n=2,117		NA/NOS n=1,495	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	91.6	93.5	84.8	86.1	53.7	55.1	73.9	76.6
2	84.3	87.8	68.4	70.3	34.5	35.9	63.0	67.0
3	78.8	83.7	57.3	59.5	23.8	25.2	55.5	60.2
4	74.6	80.7	50.1	52.7	17.5	18.8	50.8	56.2
5	71.2	78.5	45.3	48.3	14.6	16.0	48.5	54.6
6	68.1	76.5	41.9	45.1	12.0	13.3	46.4	53.1
7	65.2	74.7	38.9	42.3	10.8	12.2	43.8	51.0
8	62.8	73.5	36.3	40.0	9.6	11.1	42.0	49.8
9	60.4	72.1	34.6	38.6	9.3	10.8	40.2	48.4
10	58.6	71.4	33.4	37.7	8.7	10.2	38.3	46.9


**Table 4f.** Observed (obs.) and relative (rel.) survival of patients with fem. genitale cancer by extent of disease for period 1988-2014 (N=19,787).



**Figure 4g.** Relative survival of patients with fem. genitale cancer by extent of disease. For 15,440 of 16,411 cases diagnosed between 1998 and 2014 valid data could be obtained for this item. For a total of 15,341 cases an evaluable classification was established. The grey line represents the subgroup of 1,070 patients with missing values regarding extent of disease (6.5% of 16,411 patients, the percent values of all other categories are related to n=15,341).

Years	Extent of disease							
	Local n=11,399		Regional n=2,134		Distant n=1,808		NA/NOS n=1,070	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	92.0	93.9	85.1	86.4	53.7	55.1	68.9	71.7
2	85.4	88.8	68.7	70.7	35.1	36.5	57.5	61.6
3	80.0	84.7	57.8	60.2	24.7	26.1	49.2	53.7
4	76.0	82.0	50.1	52.9	18.4	19.8	44.4	49.6
5	72.6	79.8	45.5	48.6	15.4	16.9	42.1	47.8
6	69.4	77.6	42.4	45.7	12.6	14.0	39.9	46.2
7	66.7	76.0	39.4	42.9	11.3	12.8	37.4	43.8
8	64.4	74.9	36.7	40.6	10.3	11.8	35.5	42.5
9	62.3	73.9	35.0	39.1	9.9	11.5	33.9	41.4
10	60.5	73.1	33.4	37.8	9.0	10.6	32.7	40.3

**Table 4h.** Observed (obs.) and relative (rel.) survival of patients with fem. genitale cancer by extent of disease for period 1998-2014 (N=15,341).




**Figure 4i.** Conditional relative 5-year survival of patients with fem. genitale cancer by extent of disease. For 19,918 of 21,282 cases diagnosed between 1988 and 2014 valid data could be obtained for this item. For a total of 19,787 cases an evaluable classification was established. The grey line represents the subgroup of 1,495 patients with missing values regarding extent of disease (7.0% of 21,282 patients, the percent values of all other categories are related to n=19,787).

Years	Extent of disease							
	Local		Regional		Distant		NA/NOS	
	n	Cond. surv. % 5 yrs	n	Cond. surv. % 5 yrs	n	Cond. surv. % 5 yrs	n	Cond. surv. % 5 yrs
0	15,018	78.5	2,652	48.3	2,117	16.0	1,495	54.6
1	12,975	82.1	2,105	52.5	1,069	24.2	1,053	69.8
2	11,213	85.7	1,583	60.4	627	34.1	866	76.9
3	9,843	88.7	1,211	67.4	386	44.3	735	84.0
4	8,690	90.5	970	73.6	251	57.7	648	87.7
5	7,667	92.5	802	78.5	186	65.1	583	87.5
6	6,756	93.4	659	83.5	134	77.4	536	87.5
7	5,881	95.1	537	86.4	101	85.4	475	88.3
8	5,126	95.5	448	90.2	80	94.1	426	87.7
9	4,465	95.5	393	89.4	69	93.4	382	87.4
10	3,924	95.0	341	88.8			344	87.7

**Table 4j.** Conditional relative 5-year survival of patients with fem. genitale cancer by extent of disease for period 1988-2014 (N=19,787).

Conditional relative survival rates refer to the relative survival probability, in this case for 5 years after cancer diagnosis, compared to the age- and sex-matched population (=100%) under the condition of being alive for a certain time period (x-axis in Figure 4g). The results illustrate to what extent the cancer induced mortality of particular subgroups declines in the subsequent years after detection of the malignancy. For instance, according to the presented survival statistics, patients in the subgroup extent of disease="Local", who are alive at least 3 years after cancer diagnosis, the conditional relative 5-year survival rate is 88.7% (n=9,843).




**Figure 5a.** Time to first progression of 14,612 patients with fem. genitale cancer diagnosed between 1998 and 2014 (M0 only in solid cancers) estimated by cumulative incidence function (CI, solid line) accounting for death as competing risk and by inverse Kaplan-Meier estimate (1-KM, dashed line). The frequency of events may be underestimated due to underreporting.

Years	Type of progression						
	Any type (CI)	Any type (1-KM)	Local relapse (CI)	Local relapse (1-KM)	Lymph node (CI)	Lymph node (1-KM)	Distant metastasis (CI)
	n=14,612 %	n=14,612 %	n=14,612 %	n=14,612 %	n=14,612 %	n=14,612 %	n=14,612 %
0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
1	14.8	15.0	4.3	4.6	1.1	1.2	7.3
2	24.3	24.9	8.9	10.0	2.0	2.3	13.5
3	29.0	29.9	11.5	13.2	2.7	3.1	17.2
4	31.4	32.6	12.9	15.0	3.1	3.8	19.4
5	32.9	34.4	13.9	16.3	3.4	4.2	20.8
6	34.0	35.5	14.5	17.2	3.5	4.4	21.9
7	34.8	36.5	14.9	17.8	3.6	4.6	22.7
8	35.4	37.2	15.1	18.2	3.7	4.6	23.2
9	35.8	37.8	15.4	18.6	3.8	4.8	23.6
10	36.1	38.2	15.6	19.0	3.8	4.9	23.8
11	36.3	38.4	15.7	19.2	3.9	5.1	24.2
12	36.5	38.6	15.8	19.3	4.0	5.2	24.4
13	36.7	38.9	15.9	19.5	4.0	5.2	24.8
14	36.9	39.2	16.0	19.7	4.0	5.4	25.0
15	37.0	39.4	16.1	19.9	4.0	5.4	25.0

<i>cont'd</i>	Type of progression		
	Distant metast. (1- KM)	NOS (CI)	NOS (1-KM)
	n=14,612	n=14,612	n=14,612
Years	%	%	%
0	0.0	0.0	0.0
1	7.6	2.1	2.3
2	14.5	3.2	3.7
3	18.8	3.7	4.4
4	21.4	3.9	4.7
5	23.1	4.0	4.9
6	24.5	4.1	4.9
7	25.6	4.1	4.9
8	26.3	4.1	5.0
9	26.8	4.1	5.0
10	27.1	4.1	5.0
11	27.8	4.1	5.0
12	28.1	4.1	5.0
13	28.7	4.1	5.0
14	29.0	4.1	5.0
15	29.0	4.1	5.0

**Table 5b.** Time to first progression of patients with fem. genitale cancer for period 1998-2014 (N=14,612).




**Figure 5c.** Observed post-progression survival of 4,806 patients with fem. genitale cancer diagnosed between 1998 and 2014. These 4,806 patients with documented progression events during their course of disease represent 29.4 % of the totally 16,336 evaluated cases (incl. M1, n=1,724, 10.6 %). Patients with cancer relapse documented via death certificates only were excluded (n=1,530, 9.4 %). Multiple progression types on different sites are included in the evaluation even when not occurring synchronously. The NOS (not otherwise specified) class is included under the condition, that it is the one and only progression type during the course of disease.

Medical record documentation often lacks the linguistic severity to distinguish between local relapse, regional lymph node metastasis and distant spread in solid cancers. Frequently, the statement "not specified" is the only information in registries regarding relapse of the disease. The category "Any type" denotes all cases who suffered from at least one relapse during the course of disease (incl. primary M1-status). Although, the real number of relapsed patients is likely to be much higher. The accumulated percentage of patients with local relapse or distant metastasis exceeds the 100% value because patients are potentially considered in more than one subgroup.

Years	Type of progression				
	Any type n=4,806 %	Local relapse n=1,913 %	Lymph node n=534 %	Distant metastasis n=3,528 %	NOS n=545 %
0	100.0	100.0	100.0	100.0	100.0
1	55.8	58.9	59.4	51.3	45.7
2	37.1	40.4	40.4	32.1	27.8
3	27.7	31.3	32.5	22.5	20.8
4	21.5	24.8	23.2	17.1	14.6
5	18.1	21.4	18.8	14.0	11.7
6	15.4	18.1	16.4	11.8	10.3
7	13.7	16.4	14.4	10.6	8.2
8	12.6	15.1	13.1	9.5	7.4
9	11.7	13.2	13.1	9.2	
10	10.1	10.8		8.2	

**Table 5d.** Observed post-progression survival of patients with fem. genitale cancer for period 1998-2014 (N=4,806).



**Figure 5e.** Observed post-progression (distant metastasis) survival of 4,321 patients with fem. genitale cancer diagnosed between 1988 and 2014 by period of progression.

Years	Period of progression		
	1988-1997 n=599	1998-2006 n=1,507	2007+ n=2,215
	%	%	%
0	100.0	100.0	100.0
1	45.0	47.5	54.2
2	25.6	28.7	34.8
3	15.5	20.2	24.8
4	11.5	15.3	19.0
5	9.6	12.0	16.2
6	8.0	9.8	13.8
7	7.0	9.0	11.3
8	6.3	7.8	11.3
9	6.1	7.5	
10	5.7	6.7	

**Table 5f.** Observed post-progression (distant metastasis) survival of patients with fem. genitale cancer for period 1988-2014 by period of progression (N=4,321).

## Shortcuts

MCR Munich Cancer Registry, Germany

NCI National Cancer Institute, USA

SEER Surveillance, Epidemiology, and End Results, USA

UICC Union for International Cancer Control, Geneva

DCO Death certificate only Death certificate provides the only notification to the registry.

NA Not available

NOS Not otherwise specified

OS Overall/Observed survival Overall/Observed survival (Kaplan-Meier estimate)

Date of entry: diagnosis  
Event: death from any cause

RS Relative survival Survival compared to “general population”, ratio of observed to expected survival (Ederer II method), reflecting cancer specific survival

AS Assembled survival Assembled chart of observed, expected, relative survival

CS Conditional survival Survival probability under the condition of surviving a given period of time

TTP Time to progression Time to first progression / relapse  
Date of entry: diagnosis  
Event: (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression

1-KM 1 minus Kaplan-Meier estimator (“inverse” Kaplan-Meier estimator)

CI Cumulative incidence  
Death as competing risk (according to Kalbfleisch und Prentice)

PPS Post-progression survival Survival since first progression / relapse (Kaplan-Meier estimate)  
Date of entry (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression  
Event: death from any cause

## Recommended Citation

Munich Cancer Registry. Survival ICD-10 C51-C58: Fem. genitale cancer [Internet]. 2016 [updated 2016 Apr 11; cited 2016 Jun 1]. Available from: <http://www.tumorregister-muenchen.de/en/facts/surv/sC5158E-ICD-10-C51-C58-Fem.-genitale-cancer-survival.pdf>

## Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

## Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.



# Index of figures and tables

Fig./Tbl.	Page
1a Relative survival by period of diagnosis (chart)	2
1b Survival by period of diagnosis (table)	3
2a Survival of total cohort (chart)	4
2b Survival of total cohort (table)	4
3a Observed survival by age category (chart)	5
3b Relative survival by age category (chart)	5
3c Survival by age category (table)	6
4a Relative survival by ICD-10 classification 1988+ (chart)	7
4b Survival by ICD-10 classification 1988+ (table)	7
4c Relative survival by ICD-10 classification 1998+ (chart)	8
4d Survival by ICD-10 classification 1998+ (table)	8
4e Relative survival by extent of disease 1988+ (chart)	9
4f Survival by extent of disease 1988+ (table)	9
4g Relative survival by extent of disease 1998+ (chart)	10
4h Survival by extent of disease 1998+ (table)	10
4i Conditional survival by extent of disease (chart)	11
4j Conditional survival by extent of disease (table)	11
5a Time to first progression (chart)	12
5b Time to first progression (table)	12
5c Observed post-progression survival (chart)	14
5d Observed post-progression survival (table)	14
5e Observed post-progression survival by period of progression (chart)	15
5f Observed post-progression survival by period of progression (table)	15